Newborn Screening for X-Linked Adrenoleukodystrophy in Nebraska: Initial Experiences and Challenges.

Area of Science:

• Genetics
• Neurology
• Metabolic Disorders

Background:

• X-linked adrenoleukodystrophy (X-ALD) is a severe neurodegenerative disorder.
• It stems from ABCD1 gene variants, impairing very long-chain fatty acid metabolism.
• X-ALD presents as childhood cerebral ALD (ccALD) or adult adrenomyeloneuropathy (AMN).

Purpose of the Study:

• To evaluate the implementation and findings of newborn screening for X-ALD in Nebraska.
• To determine the birth prevalence of X-ALD in a defined population.
• To highlight challenges in genetic counseling and the need for surveillance.

Main Methods:

• Newborn screening for X-ALD using C26:0-lysophosphatidylcholine in dried blood spots.
• Genetic analysis of ABCD1 in infants with positive screening results.
• Retrospective analysis of screening data over 3.3 years.

Main Results:

• 82,920 newborns were screened, identifying 13 positive infants (4 males, 9 females).
• The birth prevalence was 1:10,583 in males and 1:4510 in females.
• All positive infants had ABCD1 variants, confirming screening accuracy.

Conclusions:

• Newborn screening for X-ALD is feasible and identifies affected infants.
• Early detection allows for potential intervention, improving outcomes for ccALD.
• Challenges include genotype-phenotype correlation and counseling for variants of uncertain significance.